Roggwil, May 2nd, 2022 – Due to the explosive increase in tinnitus patients after a COVID recovery, sales of the tinniwell have increased significantly. A marked increase in the number of patients in counseling was noted last year. This subjective finding was supported by a meta-study from the University of Manchester, which found tinnitus as a long COVID in 14.8% of those who had recovered from COVID.
In April 2022 alone, sales of the tinniwell increased by 323% compared to the previous year. Since Europe and the USA are actually pursuing an infection strategy (elimination of the obligation to wear masks, etc.), a further multiplication of sales of the tinniwell must be expected. Since January 2022, there has been an increase in infections with the new Omicron variants B.4 and B.5 in South Africa. Any of these mutations can also cause tinnitus and the University of Manchester study included patients with up to 4 COVID infections.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
T. +41 714500668